Cardiovascular
ICON's cardiovascular trial experience, supported by a global team of experts
Obesity and beyond
Embracing multi-indication potential during clinical development
The obesity therapeutic marketplace has rapidly embraced multi-indication drug development, following successful label expansion of incretin agonists semaglutide and tirzepatide. Explore the rise of multi-indication drug development across cardiometabolic-related conditions and the strategies driving clinical and commercial success for molecules with broad potential.
.jpeg?crop=yes&w=310&h=310&itok=0TSwfTVm "obesity_scan_icons"){kind=icon}
Survey report
How today’s obesity developers are navigating a multi-indication landscape
From January 24 to March 5, 2025, ICON conducted a survey of 155 developers in obesity and related comorbidities. Survey respondents shared their clinical development and commercialisation strategies for molecules with broad clinical and commercial potential, and factors influencing whether or not to pursue multi-indication development of agents in their pipeline.
.jpeg?crop=yes&w=310&h=310&itok=C8L7ju0i "obesity scan person"){kind=icon}
A multifaceted risk factor: Addressing obesity's impact across the disease spectrum
With obesity as a risk factor across the disease spectrum, there are several unique considerations and strategies for sponsors and researchers to account for in their approach to development and clinical trials for obesity treatment.
Mitigating the impact of COVID-19 on cardiovascular trials
COVID-19 has had a significant impact on the conduct of clinical trials and participants. Participants in cardiovascular (CV) trials typically are older, with underlying CV disease or risk factors such as hypertension and diabetes – a population at higher risk of death from COVID-19 if they contract the virus. As a result, these individuals may have heightened concerns about participating in a clinical trial due to the potential for exposure to COVID-19. Discover measures that can be implemented in ongoing trials to ensure the safety of participants, maximise retention and maintain trial integrity.
From genomics to the coming of age glycomics
Discover how glycan biomarkers are quickly becoming key elements of cancer, cardiovascular, and gastrointestinal research, setting the stage for a new golden age of epigenetic research and personalised therapeutics.
.jpg?crop=yes&w=310&h=310&itok=qcYu7ZZ_ "Glycomics-Whitepaper_powerpoint3-(1)"){kind=icon}
Reimagining patient-centric clinical trials with the IoMT
Follow a theoretical patient through the entire clinical trial journey – from initial contact for an early study through transition to treatment with an approved product. At each stage, we explore how IoMT can increase clinical development programme efficiency by reducing the burden on patients, caregivers, pharma companies and medical device and diagnostic manufacturers.
Cardiovascular event adjudication during COVID-19 and beyond
In this webinar you will learn more about best practices for cardiovascular event adjudication across drug and device trials, including recent advances in the selection and application of connected devices.
Latest on Cardiovascular, Metabolic, and Circulation
If you would like to receive our Cardiovascular email updates, including the latest on cardiovascular clinical trials, click here to go to our preference centre.
Blogs and media articles relating to cardiovascular and metabolic clinical trials
-
0d0b.jpg "obesity scan person")
Press release: Global ICON survey shows need for more efficient obesity clinical trial design
ICON plc today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic R&D for therapies targeting obesity and its comorbidities.
-
Media article: The challenge of targeting chronic inflammation in obesity
In this article, ICON experts explore the connection of obesity and inflammation, the current treatment landscape and future treatment directions.
-
Blog: Designing clinical trials for a complex disease: Pediatric obesity
Pediatric obesity is a complex disease with multiple factors for sponsors to consider when designing and executing treatment trials.
-
Media article: Obesity trial surge puts the focus back on decentralisation
Explore the evolving obesity clinical trials landscape and the role of decentralisation and new technologies in this recent CTA article.
-
Media article: Liver disease, obesity and the value of treatment
The link between obesity and metabolic-dysfunction associated steatotic liver disease (MASLD), and touches on recent advancements in effective treatments for obesity.
-
Media article: Pharma’s obsession with obesity on rise
ICON experts, Jack Martin and Simon Bruce share insights with BioSpectrum Asia on emerging trends in obesity treatment and the future implications for pharma.
-
Media article: Paediatric clinical trials for obesity treatment
In this article, ICON experts Alan Baldridge and Heather Peterson discuss the prevalence of paediatric obesity and assess clinical trials of its treatments.
-
Media article: Taking Stock of Obesity Drug Development: Trends and challenges facing today’s researchers
In this article, ICON’s Jack Martin discusses the direction obesity drug research is heading, and the challenges faced by researchers.
.jpeg?crop=yes&w=2048&h=1077&a=0,88&itok=-vN63p-h "obesity scan person"){kind=icon}
Cardiovascular clinical trials services at ICON
ICON has over 25 years' experience conducting cardiovascular trials, with particular emphasis on key cardiovascular/metabolic indications: heart failure, lipid disorders, diabetes, renal insufficiency and renal transplant, arrhythmia, and rare diseases.